Align Technology, Inc. — Q3 2026 Form 10-Q
Reporting period: Three and nine months ended September 30, 2026. Amounts are in U.S. dollars; financial statement figures are unaudited.
Financial performance
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | $1,014.8m | $995.7m | $3,111.0m | $2,987.4m |
| Gross profit / margin | $697.5m / 68.7% | $639.2m / 64.2% | $2,191.5m / 70.4% | $2,027.4m / 67.9% |
| Operating income / margin | $169.2m / 16.7% | $96.3m / 9.7% | $465.1m / 15.0% | $390.4m / 13.1% |
| Net income | $135.0m | $56.8m | $356.1m | $274.6m |
| Diluted EPS | $1.90 | $0.78 | $4.98 | $3.77 |
- Q3 revenue grew 1.9% year over year; nine-month revenue grew 4.1%. Clear Aligner revenue rose 4.2% in Q3 and 6.6% year to date, while Systems and Services revenue declined 7.6% and 6.1%, respectively.
- Q3 Clear Aligner case volume increased 6.6% to 690,600 shipments; nine-month volume rose 6.9% to 2.07 million. Q3 revenue per case shipment fell 2.4% to $1,215, reflecting lower-priced product and geographic mix.
- Management attributed stronger gross margins mainly to operational efficiencies and tariff refunds; Q3 also benefited from the roll-off of accelerated depreciation. Lower average selling prices partly offset those benefits.
- Q3 effective tax rate was 20.6%, versus 40.1% a year earlier; nine-month rate was 23.9%, versus 32.8%. Lower U.S. taxes on foreign earnings and jurisdictional income mix contributed to the declines.
Cash, liquidity and capital allocation
- Cash and cash equivalents were $1,144.9m at September 30, up from $1,094.9m at December 31, 2025. Current assets were $2,726.1m and current liabilities $1,913.5m.
- Nine-month operating cash flow was $526.7m, versus $370.0m; investing cash outflow was $260.8m, versus $76.5m; financing cash outflow was $210.5m, versus $367.2m. Cash, cash equivalents and restricted cash increased $50.1m over the period.
- Investing outflows included $111.5m of capital expenditures, $100.5m of equity investments, $71.9m in convertible notes and $19.0m for an acquisition; $42.0m was received from the sale of property and equipment.
- No revolver borrowings were outstanding; the full $300m unsecured facility was available, and the company reported covenant compliance. Management believes cash and borrowing capacity are sufficient for at least 12 months. No funded-debt balance is clearly presented in the supplied filing text.
- The company repurchased $201.2m of stock during the first nine months and had $630m remaining under its $1bn program at quarter-end. It repurchased an additional $30m in October, leaving $600m available.
Material developments, outlook and risks
- Outlook and investment: No specific revenue or earnings guidance is provided. Management expects 2026 capital expenditures of $125m–$150m. A planned Hyderabad manufacturing facility is expected to begin operations in 2027, with an estimated multiyear investment of about $200m; management does not expect a material near-term liquidity impact.
- Restructuring: A new 2026 workforce realignment is expected to cost $35m–$37m. The company had recorded $28.5m in charges by September 30, including $11.2m in cost of revenue and $17.2m in restructuring expense; $20.7m remained unpaid. The 2025 plan is complete, with no further charges expected under that plan.
- UK VAT: The Upper Tribunal ruled that UK clear aligners are subject to VAT. Align accrued an estimated $43.1m liability, including interest, and is appealing. Invoices due to UK customers included VAT effective September 7, 2026.
- Litigation: Align accrued $32.7m for legal settlements, substantially related to a $32m settlement in principle with the Snow antitrust plaintiffs. On October 5, 2026, after quarter-end, the Ninth Circuit reversed and remanded a separate antitrust case and also reversed the Snow matter; Align said the Snow ruling was moot in light of the settlement. Other patent disputes remain active, with outcomes and potential damages uncertain.
- Operating risks: Management cited consumer and doctor uncertainty, slower orthodontic starts, competition and product mix pressure, tariffs and trade policy, foreign exchange, inflation, and geopolitical tensions. It also highlighted reliance on certain sole-source suppliers and ongoing litigation and regulatory risks. Foreign currency movements adversely affected Q3 revenue.
- Other unusual items: The company recorded a $11.7m gain in Q1 from revaluing a Mexico manufacturing disposal group and completed its sale in Q2 for about $42m. Nine-month results included $15.6m of accelerated depreciation, which reduced net income by $11.9m, or $0.17 per diluted share.
Important facts for investors to verify
- Whether clear-aligner volume growth can continue to offset lower average selling prices and the Systems and Services revenue decline.
- The outcome and cash cost of the UK VAT appeal, the Snow settlement and other antitrust and patent proceedings.
- Final 2026 restructuring costs and the timing and total cost of the Hyderabad facility investment.
- Cash conversion and working-capital trends, particularly the nine-month outflows from receivables and deferred revenue.
- Potential effects of tariffs, currency movements, consumer demand and supply-chain or geopolitical disruptions on margins and sales.